This collection of content will continually bring you the latest news, research and FDA approvals relating to leukemia and lymphoma.
New Video! Accelerated Pace of Advances
William G. Wierda, MD, PhD, section chief, Chronic Lymphocytic Leukemia, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, discusses the exciting advances in CLL over the past 5 years.
New Article! New Study Suggests Antibody-Based Drug Safe in Treating CLL
Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the "stemness" of chronic lymphocytic leukemia (CLL) cells.
New Article! Combination Therapy as First-Line Approach for Chronic Lymphocytic Leukemia
The phase III iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival (PFS). The study evaluated ibrutinib in combination with obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) patients.